The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.

The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.

The present invention is situated in the field of mineral micro-particles selected from the list consisting of aluminum hydroxide, aluminum phosphate, amorphous aluminium hydroxyphosphate and calcium phosphate micro-particles. More particularly, the invention provides organically-derivatized mineral micro-particles, uses thereof, and methods of preparing the same.

A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes. ##STR00001##

A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes. ##STR00001##

To provide a novel boron-containing compound. A compound represented by the following formula: wherein black circle represents B, white circles represent B—H; —R.sup.1 represents —(CH.sub.2)n-X.sup.1—R.sup.3 (n represents an integer of 0 to 6; X.sup.1 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; R.sup.3 represents C.sub.6-C.sub.20 alkyl, hydroxy C.sub.6-C.sub.20 alkyl, amino C.sub.6-C.sub.20 alkyl, azido C.sub.6-C.sub.20 alkyl, hydroxycarbonyl C.sub.6-C.sub.20 alkyl, or the like), or a group having a repeating sequence of —(CH.sub.2).sub.2—O— 3 times or more and 10 times or less and having a methyl group or an ethyl group at the end on the oxygen atom side; and —R.sup.2 is —(CH.sub.2)m-X.sup.2—R.sup.4 (m represents an integer from 0 to 8; X.sup.2 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; and R.sup.4 represents a tumor recognition moiety), or does not exist are prepared and used. ##STR00001##

To provide a novel boron-containing compound. A compound represented by the following formula: wherein black circle represents B, white circles represent B—H; —R.sup.1 represents —(CH.sub.2)n-X.sup.1—R.sup.3 (n represents an integer of 0 to 6; X.sup.1 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; R.sup.3 represents C.sub.6-C.sub.20 alkyl, hydroxy C.sub.6-C.sub.20 alkyl, amino C.sub.6-C.sub.20 alkyl, azido C.sub.6-C.sub.20 alkyl, hydroxycarbonyl C.sub.6-C.sub.20 alkyl, or the like), or a group having a repeating sequence of —(CH.sub.2).sub.2—O— 3 times or more and 10 times or less and having a methyl group or an ethyl group at the end on the oxygen atom side; and —R.sup.2 is —(CH.sub.2)m-X.sup.2—R.sup.4 (m represents an integer from 0 to 8; X.sup.2 represents O, S, NH, S—S, O—CO, NHCO or SCO, or does not exist; and R.sup.4 represents a tumor recognition moiety), or does not exist are prepared and used. ##STR00001##

The present disclosure describes glucose analogs that are transported on the sodium dependent glucose transporters (SGLTs). These compounds may be useful in a variety of disorders such as, for example, cancer, heart disease, neurological disorders, diabetes, and atherosclerosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present disclosure describes glucose analogs that are transported on the sodium dependent glucose transporters (SGLTs). These compounds may be useful in a variety of disorders such as, for example, cancer, heart disease, neurological disorders, diabetes, and atherosclerosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO.sub.2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.